Jeanne Palmer, MD, Mayo Clinic, Phoenix, AZ, talks on the importance of understanding the mechanism of action of new disease-modifying therapies in myelofibrosis (MF) to prevent treatment-related clonal evolution and disease progression. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.